AGTR2: A Potential Drug Target and Biomarker (G186)

Target Name: AGTR2

NCBI ID: G186

AGTR2

AGTR2: A Potential Drug Target and Biomarker

Autosomal genetic variation has been identified as a risk factor for the development of various diseases, including cardiovascular diseases, metabolic disorders, and neurological conditions. One of the most promising avenues for targeting these diseases is the identification of genetic variants that can be used to predict the response to therapeutic interventions. One such genetic variant is AGTR2, which has been identified as a potential drug target and biomarker for various diseases.

AGTR2 (Autosomal Genetic Variant Receptor 2) is a gene that encodes a protein known as the AGTR2 receptor. The AGTR2 receptor is a transmembrane protein that is expressed in various tissues and cells throughout the body, including the brain, heart, kidneys, and intestines. It is involved in the regulation of cell signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a critical regulator of cell growth, differentiation, and survival, and is implicated in the development and progression of many diseases, including cardiovascular diseases, metabolic disorders, and neurological conditions. The AGTR2 receptor is a key regulator of TGF-β signaling in the brain, and has been implicated in the development of various neurological conditions, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

In addition to its role in TGF-β signaling, the AGTR2 receptor is also involved in the regulation of neurotransmitter signaling, pain perception, and inflammation. It has been shown to play a role in the regulation of dopamine release from brain neurons, which is implicated in the treatment of addiction and other neurological disorders.

Given the involvement of the AGTR2 receptor in the regulation of TGF-β signaling and other processes, it is a promising target for therapeutic interventions. Several drugs that have been shown to modulate TGF-β signaling have been approved for use in clinical trials for various diseases, including cancer, cardiovascular diseases, and neurorological conditions.

In addition to its potential as a drug target, the AGTR2 receptor is also a potential biomarker for several diseases. The AGTR2 receptor is expressed in various tissues and cells throughout the body, including the brain, heart, and kidneys, and can be used as a marker for the diagnosis and assessment of disease.

For example, AGTR2 gene variants have been identified as potential biomarkers for several diseases, including cardiovascular disease, metabolic disorders, and neurological conditions. Several studies have shown that individuals with certain AGTR2 gene variants are at increased risk for the development of these diseases. For example, research has shown that individuals with the AGTR2 gene variant associated with increased risk for cardiovascular disease may benefit from additional screening and preventive interventions, such as lifestyle modifications and medications that target the AGTR2 receptor.

In conclusion, AGTR2 is a promising drug target and biomarker for various diseases. Its involvement in the regulation of TGF-β signaling and its potential as a marker for disease make it an attractive target for therapeutic interventions. Further research is needed to fully understand the role of AGTR2 in disease and to develop safe and effective treatments.

Protein Name: Angiotensin II Receptor Type 2

Functions: Receptor for angiotensin II, a vasoconstricting peptide (PubMed:8185599, PubMed:28379944, PubMed:29967536, PubMed:31899086). Signals primarily via a non-canonical G-protein- and beta-arrestin independent pathways (PubMed:28379944). Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation (PubMed:15123706)

The "AGTR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGTR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets